Cell Therapy News

Researchers have discovered a link between neurotoxicity related to chimeric antigen receptor T-cell therapy and development of subsequent hypophosphatemia.

The basic science discoveries to which Helen E. Heslop, MD, DSc (Hon), has contributed place her firmly on the Mount Rushmore of pioneers in the field of gene and cell therapy.

The FDA granted regenerative medicine advanced therapy designation to CTX130, a chimeric antigen receptor T-cell therapy under development for the treatment of mycosis fungoides and Sézary syndrome.

Parker Institute for Cancer Immunotherapy added Dana-Farber Cancer Institute and Gladstone Institutes to its immuno-oncology research partnership network.

Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has allowed those who require treatment to benefit from the groundbreaking development of chimeric antigen receptor T cells.

The FDA granted orphan drug designation to KITE-222, an investigational chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory acute myeloid leukemia.

The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell therapy, for treatment of mesothelin-expressing mesothelioma.

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.

Nina Bhardwaj, MD, PhD, has spent her career investigating dendritic cells and identifying novel cancer-specific antigens with the goal of developing an off-the-shelf vaccine for treatment, work that has recently garnered recognition.

A single infusion of tumor-infiltrating lymphocytes more than doubled PFS, OS and complete response rates compared with ipilimumab among patients with advanced, unresectable melanoma, study results presented at ESMO Congress showed.